James H

James Healy, MD, PhD, is Managing Partner at Sofinnova Investments, where he leads the firm’s investment activities with a focus on innovative biotechnology startups in clinical and late preclinical drug development. He sits on the boards of companies such as CinCor Pharma, Bolt Biotherapeutics, ArriVent BioPharma, Rapport Therapeutics, BioAge Labs, and Seaport Therapeutics, underscoring his active involvement in advancing new therapeutics within the biopharmaceutical sector.

Healy specializes in the biopharma industry, particularly in emerging therapeutics targeting oncology, neuroscience, cardiometabolic diseases, and age-related conditions. He has helped guide multiple companies from early-stage financings through IPOs, with notable exits including Karuna Therapeutics and leadership in recent megarounds for clinical-stage biotech firms.

A physician-scientist by training, Healy holds an MD and PhD in Immunology from Stanford University, as well as bachelor’s degrees in Molecular Biology and Scandinavian Studies from the University of California, Berkeley. His expertise combines deep scientific acumen with strategic investment judgment, making him a prominent figure in life sciences venture capital.